Abbott Laboratories (ABT)
Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is The Fall In Abbott Stock Justified?
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, aligning with expectations, while the total annual adjusted EPS reached $5.15, indicating a 10% growth.
Abbott Laboratories: Buy This Dividend King On Sale Now
Last month, Abbott Laboratories hiked its dividend for the 54th consecutive year. The company's FreeStyle Libre and Volt PFA System franchises, as well as its pending acquisition of Exact Sciences, position it for strong growth. Abbott Laboratories boasts a vigorous interest coverage ratio.
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Jobless Claims Stay Low at +200K, Q3 GDP Up to +4.4%
Weekly Jobless Claims continue to portray a labor market cruising along at a healthy low rate of unemployment claims.
Abbott's Q4 Earnings Meet Estimates, Revenues Miss, Stock Falls
ABT's Q4 earnings meet estimates but revenues miss, sending shares down as strong device growth is offset by weaker nutrition and diagnostics sales.
Abbott (ABT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (ABT) Matches Q4 Earnings Estimates
Abbott (ABT) came out with quarterly earnings of $1.5 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.34 per share a year ago.
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
2 Healthcare Names That Could Get a Big Boost From Earnings
Active traders expect companies in the healthcare sector to experience significant share price spikes tied to milestones in the development of new therapies and medical products. The volatility in some corners of the sector makes it a high-risk, but high-reward, opportunity.
Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings?
ABT heads into Q4 earnings with adult nutrition in focus, as Ensure and Glucerna launches are expected to support modest segment growth.
